CLCéline La

Céline La

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Céline La has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Alina Ferster

    Department of Pediatric Rheumatology, Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Belgium

    3 shared publications
  • Bernard Lauwerys

    Department of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

    3 shared publications
  • Laurence Goffin

    Department of Pediatric Rheumatology, Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Belgium

    3 shared publications
  • Phu Quoc Lê

    Department of Pediatric Rheumatology, Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Belgium

    3 shared publications
  • Tatiana Sokolova

    Institut de Recherche expérimentale et Clinique (IREC), Université catholique de Louvain Secteur des sciences de la santé, Bruxelles, Belgium

    3 shared publications
  • Valérie Badot

    Department of Rheumatology, CHU Brugmann, Bruxelles, Belgium

    3 shared publications

Latest Publications

  • Open Access

    Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases

    by Céline La, Julie Smet, Carole Nagant, Muhammad Soyfoo

    Anti-Ku antibodies are rare autoantibodies associated with connective tissue diseases (CTDs), but their clinical significance remains poorly understood due to limited studies. Semi-quantitative immunodot assays yield positive, negative, or borderline results, with the clinical relevance of borderline findings remaining unclear. The purpose of this study is to characterize the clinical spectrum of anti-Ku-positive patients and evaluate the clinical significance of anti-Ku-borderline results in CTD management. A retrospective cohort study was conducted at Hôpital Erasme, including all patients with anti-Ku-positive or borderline results, over a 10-year period. Clinical and biological data were collected from medical records and analyzed for disease associations, organ involvement, and outcomes. Among 47 anti-Ku-positive patients, systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS) were the most common diagnoses. Interstitial lung disease (ILD) occurred in 23.4% and renal involvement in 12.8% of patients. Cytopenia was significantly associated with glomerulonephritis. Organ damage, particularly pulmonary and renal involvement, correlated with increased mortality. In the borderline group (n = 33), SLE and SS remained the predominant diagnoses. During follow-up, three patients died (all with isolated ILD without associated CTD), one required chronic dialysis, and one underwent lung transplantation. ILD was present in 7/22 (31.8%) borderline patients, and renal involvement in 7/32 (21.9%). This study demonstrates significant associations between anti-Ku antibodies and organ damage, with increased mortality risk. The high prevalence of pulmonary and renal involvement in anti-Ku-borderline patients suggests that these results carry substantial clinical significance and should prompt comprehensive CTD evaluation. These findings support treating borderline anti-Ku results with the same clinical vigilance as positive results, given their similar association with severe organ involvement and adverse outcomes.


  • Open Access

    Plasmacytosis and nephrotic syndrome revealing Sjögren’s syndrome

    by Céline LA, Muhammad Soyfoo

    Sjögren’s syndrome is an autoimmune disease characterized by the lymphocytic infiltration of exocrine glands resulting in dry eyes and mouth but can also cause multi-organ damage.[1] Renal involvement is rare during primary Sjögren’s syndrome, occurring in 3 to 5% of patients, and even rarely resulting in end-stage renal disease (5%).[2-5] We herein report the case of a 43-year-old female patient admitted to our hospital with sudden onset dyspnea, abdominal pain, diffuse edema, weight gain of 7 kg, dyspepsia and polyarthralgia. The patient had been recently diagnosed with systemic erythematosus lupus based on polyarthralgia, normocytic anemia and positivity of antinuclear antibody and anti-Sjögren’s syndrome type A (anti-SSA) antibody. The laboratory investigations showed an acute kidney injury with nephrotic syndrome, anti-SSA and anti- Sjögren’s syndrome type B (anti-SSB) antibody positivity, low complement component 4 levels and hypergammaglobulinemia. Cryoglobulinemia was excluded. A percutaneous kidney biopsy was performed the day after her admission. The patient was rapidly treated with high-doses of intravenous corticosteroids, but her clinical condition and renal failure worsened with an estimated glomerular filtration rate of 19 mL/min. The kidney biopsy revealed acute tubulointerstitial nephritis with massive lymphoplasmacytic infiltrate positive for anti-cluster of differentiation 20 antibody and no expression of anti-immunoglobulin G4 antibody (Figure 1a, b). Because of the important lymphocytic infiltrate, a bone marrow biopsy was performed to exclude lymphoma and showed a rich marrow cellularity with polyclonal plasmacytosis (Figure 1c, d). Positron emission tomography (PET)-fluorodeoxyglucose (FDG) scan did not demonstrate any enlarged lymph nodes or hepatosplenomegaly in favor of lymphoma or Castleman disease. Schirmer’s test came back positive and a minor salivary gland biopsy depicted lymphocytic sialadenitis with a Chisholm and Mason score of 4 (Figure 1e, f). Electromyography results showed inflammatory polyradiculoneuritis in C6 and C7. A gastric emptying scan was consistent with gastroparesis. Moreover, immunohistochemistry results of the kidney biopsy also came back negative for human herpesvirus 8 (HHV8) antibody. The absence of the typical histological signs, as well as HHV8 negativity and normal PET-FDG ruled out Castleman disease. Our patient presented primary Sjögren’s syndrome with complex systemic manifestations, including renal, hematological (lymphoproliferative syndrome), neurological (polyradiculoneuritis and gastroparesis) and articular disease. The patient was treated with rituximab and oral steroids with good clinical and biological improvement. Cyclophosphamide and steroids were started a year later for a renal flare but suspended because of a major hematological toxicity and the patient had to undergo chronic hemodialysis. Finally, she received a renal transplant from a non-heart-beating-donor five years after initial diagnosis and is currently treated with tacrolimus and mycophenolate. A written informed consent was obtained from the patient. In conclusion, renal involvement is rare in primary Sjögren’s syndrome. Tubulointerstitial nephritis represents the largest majority of cases, while glomerular lesions are rather associated with cryoglobulinemia.[6,7] The prognosis is usually favorable, but the patients should be carefully screened if renal involvement is suspected, because of the risk of developing chronic kidney disease. Furthermore, a renal biopsy should be discussed to exclude other causes of renal insufficiency and to guide the therapeutic decision.

  • Open Access

    Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis

    by Céline La, Phu Quoc Lê, Alina Ferster, Laurence Goffin, Delphine Spruyt, Bernard Lauwerys, Patrick Durez, Cecile Boulanger, Tatiana Sokolova, Joanne Rasschaert, et al.

    Introduction In the management of juvenile idiopathic arthritis (JIA), there is a lack of diagnostic and prognostic biomarkers. This study assesses the use of serum calprotectin (sCal) as a marker to monitor disease activity, and as a classification and prognosis tool of response to treatment or risk of flares in patients with JIA. Methods Eighty-one patients with JIA from the CAP48 multicentric cohort were included in this study, as well as 11 non-paediatric healthy controls. An ELISA method was used to quantify sCal with a commercial kit. Results Patients with an active disease compared with healthy controls and with patients with inactive disease showed an eightfold and a twofold increased level of sCal, respectively. sCal was found to be correlated with the C-reactive protein (CRP) and even more strongly with the erythrocyte sedimentation rate. Evolution of DAS28 scores correlated well with evolution of sCal, as opposed to evolution of CRP. With regard to CRP, sCal could differentiate forms with active oligoarthritis from polyarthritis and systemic forms. However, sCal brought an added value compared with the CRP as a prognosis marker. Indeed, patients with active disease and reaching minimal disease activity (according to Juvenile Arthritis Disease Activity Score) at 6 months following the test had higher sCal levels, while patients with inactive disease had higher sCal levels if a flare was observed up to 3–9 months following the test. Conclusions This study confirms the potential uses of sCal as a biomarker in the diagnosis and follow-up of JIA.


  • Open Access

    Serum Calprotectin (S100A8/A9): A Promising Biomarker in Diagnosis and Follow-up in Different Subgroups of Juvenile Idiopathic Arthritis

    by Céline La, Phu Quoc Lê, Alina Ferster, Laurence Goffin, Delphine Spruyt, Bernard Lauwerys, Patrick Durez, Cecile Boulanger, Tatiana Sokolova, Joanne Rasschaert, et al.

    IntroductionIn the management of juvenile idiopathic arthritis (JIA), there is a lack of diagnostic and prognostic biomarkers. This study assesses the use of serum calprotectin (sCal) as a marker to monitor disease activity, and as a classification and prognosis tool of response to treatment or risk of flares in patients with JIA. MethodsEighty-one patients with JIA from the CAP48 multicentric cohort were included in this study, as well as 11 non-pediatric healthy controls. An enzyme-linked immunosorbent assay (ELISA) method was used to quantify sCal with a commercial kit.ResultsPatients with an active disease compared to healthy controls and to patients with inactive disease showed an 8-fold and a 2-fold increased level of sCal respectively. sCal was found to be correlated with the CRP and even more strongly with the ESR. Evolution of DAS28 scores correlated well with evolution of sCal, as opposed to evolution of CRP. With regard to CRP, sCal could differentiate forms with active oligoarthritis from polyarthritis and systemic forms. However, sCal brought an added value compared to the CRP as a prognosis marker. Indeed, patients with active disease and reaching minimal disease activity (according to JADAS) at 6 months following the test had higher sCal levels, while patients with inactive disease had higher sCal levels if a flare was observed up to 3 to 9 months following the test.ConclusionsThis study confirms the potential uses of serum calprotectin as a biomarker in the diagnosis and follow-up of JIA.


  • Open Access

    Preliminary Results of first Belgian Cohort of Juvenile Idiopathic Arthritis: Where Do we Stand in Terms of Quality of Care and Remission?

    by Céline La, Phu Quoc Lê, Alina Ferster, Laurence Goffin, Bernard Lauwerys, Patrick Durez, Cécile Boulanger, Viviane De Maertelaer, Tatiana Sokolova, Valérie Badot

    IntroductionJuvenile idiopathic arthritis (JIA) represents a very heterogeneous disease. As such, it has been a challenge to describe the disease activity of JIA cohorts. Our objective was to describe the first Belgian cohort of children with JIA by assessing their disease characteristics, outcomes, and potential markers of prognosis.MethodsThe CAP48 cohort is a multicentric observational study of children with recent or well-established diagnosis of JIA (naïve or not to treatment at baseline), evaluated every 3 to 6 months during a follow-up of 10 years.ResultsThere were 125 children included, composing of 25 naïve and 100 established patients. Their median age at onset was 6.2 and 4.2 years in the naïve and established cohort respectively, with a predominance of female. All subtypes of JIA were represented in both cohorts. The mean DAS28-CRP and JADAS10-CRP at baseline in naïve patients was 2.52 and 6.0 respectively. Uveitis occurred in 19% of patients and was strongly associated with presence of antinuclear antibodies (odds ratio of 6). Among naïve patients, 55% were in remission at 12 months according to ACR criteria and JADAS10 scores, in contrast with 100% achieving DAS28 remission. ConclusionThis first cohort study in Belgium allowed to compare its data to other existing cohorts and to evaluate quality of care in Belgian French-speaking hospitals. Additionally, it highlighted a superiority of JADAS10 over DAS28 to monitor and evaluate remission in JIA. This study also underlined a need for more accurate markers of prognosis to improve treatment and long-term outcomes.